

Provident Clinical Research

Kathleen Kelley, MD

kkelley@providentcrc.com • www.providentcrc.com

211 E. Lake Street
Addison, IL 60101
Tel: (630) 617-2000
Fax: (630) 617-2001

PROFESSIONAL EXPERIENCE:

2009-Present	Clinical Investigator Provident Clinical Research Addison, Illinois
2004-Present	Corporate Health/Employee Health Physician Edward Hospital Naperville, Illinois
2004-Present	Independent Physician Consultant MetLife Disability
2004-2005	Home Care Physician Rockford, IL
1994-2003	Clinic Physician OMNI Work Injury Clinic Glendale Heights, Illinois
1994-2003	Instructor of Occupational Medicine Hinsdale Hospital Hinsdale, Illinois
1988-2004	Urgent Care Physician Glen Ellyn Clinic Glen Ellyn, IL
1986-1988	Staff Physician Saran and Dan Medical Associates Downers Grove, IL

EDUCATION:

1982-1985	Internal Medicine Residency Loyola University Medical Center Maywood, Illinois
1982	Doctor of Medicine Medical College of Ohio Toledo, Ohio
1979	Bachelor of Arts in Psychology, Magna Cum Laude University of Toledo Toledo, Ohio

CERTIFICATION:

Current	Illinois State License
Current	American Board of Internal Medicine

PROFESSIONAL SOCIETIES:

1995-Present	Medical Review Officer-MROCC
1994-Present	American College of Occupational and Environmental Medicine

KEY ACCOMPLISHMENTS:

- Instructor in Occupational Medicine for nurse continuing education
 - Edward Hospital Naperville, Illinois

RESEARCH PARTICIPATION (CONFIDENTIAL INFORMATION REPRESENTED WITH XXX):

1. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and safety of XXX Therapy in Subjects with Severe Hypertriglyceridemia. (2010, Clinical Investigator)
2. A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP STUDY OF XXX VS. XXX IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA. (2010, Clinical Investigator)
3. A Randomized, Double-Blind, Controlled, Crossover Trial to assess the Acute Effects of Two Doses of XXX on Endothelial Function in Women (2010, Principal Investigator) Sponsor: Welch Foods Inc., a Cooperative
4. A Randomized, Controlled, Crossover Trial to Assess the Effects of XXX on Exercise Performance at Two Intensities in Healthy Men (2010, Principal Investigator) Sponsor: The Coca-Cola Company
5. A Study to Determine Eligibility for a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Designed to Assess the Effects of XXX on Lactate Threshold in

- Trained Cyclists (2010, Principal Investigator) Sponsor: PepsiCo Global Long Term Research
6. A Single-blind Pilot Study to Assess XXX from a Softgel Capsule Compared to a Standard Tablet (2010, Principal Investigator) Sponsor: Pharmavite, LLC
 7. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of XXX on Oxidized LDL (2010, Clinical Investigator) Sponsor: KitoZyme, Inc.
 8. Evaluation of an Oral Nutritional Supplement Containing XXX in Malnourished and Frail Subjects (2010, Clinical Investigator) Sponsor: Abbott Nutrition, Abbott Laboratories
 9. A Randomized, Controlled Trial to Assess the Effects of XXX on Eicosapentaenoic Acid Levels of Red Blood Cells and the Omega-3 Index (2010, Principal Investigator) Sponsor: Monsanto/The Solae Company
 10. A Double-Blind, Randomized, Controlled, Crossover Trial to Assess the Effects of XXX on Urinary Anti-Adhesion Activity in Healthy Men and Women (2010, Principal Investigator) Sponsor: Ocean Spray Cranberries, Inc.
 11. Effect of XXX on Metabolic Parameters in Subjects with Type 2 Diabetes (2010, Clinical Investigator) Sponsor: Abbott Nutrition, Abbott Laboratories
 12. A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of XXX on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects with Hypertriglyceridemia (2010, Clinical Investigator) Sponsor: Provident Clinical Research & Consulting, Inc.
 13. Evaluation of a Snack Food Containing XXX on Energy Intake and Satiety (2010, Clinical Investigator) Sponsor: GlaxoSmithKline Consumer Healthcare
 14. A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of XXX, on Alertness, Attention and Concentration in Healthy Men and Women (2010, Principal Investigator) Sponsor: DSM Nutritional Products Ltd
 15. A Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating the Effects of XXX on Physical Performance in Healthy Male Volunteers (2010, Principal Investigator) Sponsor: PepsiCo, Inc.
 16. Randomized, double-blind, placebo controlled Phase II study to examine the effects of XXX in healthy adult subjects with laboratory confirmed influenza (2010, Clinical Investigator) Sponsor: NexBio, Inc.
 17. A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of XXX on Low-density Lipoprotein Cholesterol and Other Aspects of the Fasting Lipid Profile in Subjects with Primary Hypercholesterolemia (2010, Clinical Investigator) Sponsor: Provident Clinical Research and Consulting, Inc.
 18. A Randomized, Controlled, Double-blind Crossover Study to Assess the Effects of a XXX, at Two Doses, on Insulin Sensitivity (2009, Clinical Investigator) Sponsor: National Starch LLC
 19. A Randomized, Controlled, Crossover Trial to Assess the Effects of XXX on Work Capacity During Exercise in Trained Male Athletes (2009, Principal Investigator) Sponsor: The Coca-Cola Company

20. A Randomized, Controlled, Parallel Trial to Evaluate the Effects of XXX on Cognitive Processes in Children 8-12 Years of Age (2009, Principal Investigator) Sponsor: Kellogg Company
21. A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effects of Two Doses of XXX on Fasting Serum Triglyceride Levels, in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy (2009, Clinical Investigator) Sponsor: Amarin Pharma Inc.
22. "A Randomized, Controlled Crossover Study to Assess the Effects of Consuming XXX as Part of a Typical American Diet on the Plasma Lipid Profile in Men and Women with Primary Hypercholesterolemia" (2009, Principal Investigator) Sponsor: Almond Board of California
23. A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of XXX in Combination with Metformin as Initial Therapy as Compared with XXX Monotherapy and Metformin Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control (2009, Clinical Investigator) Sponsor: Bristol-Myers Squibb
24. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Added to Antihypertensive Treatment with Lisinopril or Losartan in Patients with Hypertension (2009, Clinical Investigator) Sponsor: Forest Research Institute
25. "A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of XXX in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL: The XXX MARINE Study (2009, Clinical Investigator) Sponsor: Amarin Pharma Inc.
26. "A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of XXX Compared to Glipizide When Used in Combination with Metformin in Subjects with Type 2 Diabetes" (2009, Clinical Investigator) Sponsor: Takeda
27. "A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm Trial to Assess the Effects of XXX on High-Density Lipoprotein Cholesterol and Other Cardiovascular Disease Risk Markers" (2009, Clinical Investigator) Sponsor: Shaklee Corporation
28. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women" (2009, Clinical Investigator) Sponsor: BioSante Pharmaceuticals, Inc.
29. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women" (2009, Clinical Investigator) Sponsor: BioSante Pharmaceuticals, Inc.
30. A Randomized, Placebo-Controlled, Crossover Trial to Assess the Effects of XXX on Fasting Lipoprotein Lipids in Men and Women with Primary Hypercholesterolemia (Protocol B) (2009, Clinical Investigator) Sponsor: Pharmavite, LLC
31. A Randomized, Placebo-Controlled, Crossover Trial to Assess the Effects of XXX on Fasting Lipoprotein Lipids in Men and Women with Primary Hypercholesterolemia (Protocol A) (2009, Clinical Investigator) Sponsor: Pharmavite, LLC

32. A Randomized, Double-Blind, Active-Comparator, 8-Week Forced-Titration Study of the Efficacy and Safety of XXX Versus XXX in Hypertensive Subjects (2009, Clinical Investigator) Sponsor: Daiichi Sankyo, Inc.
33. Evaluation of the Relationships of Time and Dose of XXX and XXX to Changes in XXX of Red Blood Cells (2009, Clinical Investigator) Sponsor: Monsanto Company/The Solae Company
34. A Randomized, Controlled Parallel Study to Evaluate the Effects of XXX on Fecal Bile Acids and Blood Lipids in Men and Women with Mild to Moderate Hypercholesterolemia (2009, Clinical Investigator) Sponsor: The Solae Company
35. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of XXX on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance (2009, Clinical Investigator) Sponsor: Arête Therapeutics
36. A Phase III, Double-blind, Randomized, Multi-Center, Prospective, Placebo-Controlled Comparative Study to Evaluate XXX on Carotid Intima-Media Thickness (cIMT) in Subjects with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy Trial. (2009, Clinical Investigator) Sponsor: Abbott Laboratories
37. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of XXX Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients (BALANCE) (2009, Clinical Investigator) Sponsor: Akros Pharma Inc.
38. A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety of XXX in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy (2009, Clinical Investigator) Sponsor: Daiichi Sankyo, Inc.